Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Melanoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 10pembrolizumab 9Cyclophosphamide 9Flow Cytometry 7sargramostim 6Therapeutics 6Taxes 5Polymerase Chain Reaction 5Immunoenzyme Techniques 5Docetaxel 5Carboplatin 5aldesleukin 4Psychiatric Rehabilitation 4Fulvestrant 4Filgrastim 4ribociclib 3Trastuzumab 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Mass Spectrometry 3Interleukin-12 Subunit p35 3Immunologic Techniques 3Immunohistochemistry 3Gene Expression Profiling 3Amplified Fragment Length Polymorphism Analysis 3Amifostine 3talazoparib 2spartalizumab 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Propranolol × Breast × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡